Format

Send to

Choose Destination
Trends Mol Med. 2018 Feb;24(2):206-220. doi: 10.1016/j.molmed.2017.12.004. Epub 2018 Jan 31.

Focusing on the Opioid System for Addiction Biomarker Discovery.

Author information

1
McGill Group for Suicide Studies, Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, QC, Canada; Pôle de Psychiatrie, Assistance Publique Hôpitaux de Marseille, Marseille, France; INT-UMR7289,CNRS Aix-Marseille Université, Marseille, France; These authors contributed equally to this article.
2
Department of Psychiatry and Addictology, University Hospital of Strasbourg and Medical School of Strasbourg, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg, University Hospital of Strasbourg and Medical School of Strasbourg, Strasbourg, France; INSERM 1114, Department of Psychiatry and Addictology, University Hospital of Strasbourg, Strasbourg, France; These authors contributed equally to this article.
3
Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, QC, Canada.
4
McGill Group for Suicide Studies, Douglas Hospital Research Center, Department of Psychiatry, Faculty of Medicine, McGill University, Montreal, QC, Canada; Current address: Institut des Neurosciences Cellulaires et Intégratives, CNRS UPR 3212, Strasbourg, France. Electronic address: pierreeric.lutz@gmail.com.

Abstract

Substance use disorders (SUD) and behavioral addictions are devastating conditions that impose a severe burden on all societies, and represent difficult challenges for clinicians. Therefore, biomarkers are urgently needed to help predict vulnerability, clinical course, and response to treatment. Here, we elaborate on the potential for addiction biomarker discovery of the opioid system, particularly within the emerging framework aiming to probe opioid function in peripheral tissues. Mu, delta, and kappa opioid receptors all critically regulate neurobiological and behavioral processes that define addiction, and are also targeted by major pharmacotherapies used in the management of patients with SUD. We propose that opioid biomarkers may have the potential to improve and guide diagnosis and therapeutic decisions in the addiction field.

KEYWORDS:

addiction; biomarker; brain imaging; epigenetic; genetic; opioid receptor

PMID:
29396147
DOI:
10.1016/j.molmed.2017.12.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center